These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36981643)

  • 1. Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges.
    Adachi T; El-Hattab AW; Jain R; Nogales Crespo KA; Quirland Lazo CI; Scarpa M; Summar M; Wattanasirichaigoon D
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare disease emerging as a global public health priority.
    Chung CCY; ; Chu ATW; Chung BHY
    Front Public Health; 2022; 10():1028545. PubMed ID: 36339196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advocacy for health equity: a synthesis review.
    Farrer L; Marinetti C; Cavaco YK; Costongs C
    Milbank Q; 2015 Jun; 93(2):392-437. PubMed ID: 26044634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
    Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
    Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare diseases in Chile: challenges and recommendations in universal health coverage context.
    Encina G; Castillo-Laborde C; Lecaros JA; Dubois-Camacho K; Calderón JF; Aguilera X; Klein AD; Repetto GM
    Orphanet J Rare Dis; 2019 Dec; 14(1):289. PubMed ID: 31931841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
    Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
    Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare diseases research and policy in Australia: On the journey to equitable care.
    Bhattacharya K; Millis N; Jaffe A; Zurynski Y
    J Paediatr Child Health; 2021 Jun; 57(6):778-781. PubMed ID: 33861492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urban health: an example of a "health in all policies" approach in the context of SDGs implementation.
    Ramirez-Rubio O; Daher C; Fanjul G; Gascon M; Mueller N; Pajín L; Plasencia A; Rojas-Rueda D; Thondoo M; Nieuwenhuijsen MJ
    Global Health; 2019 Dec; 15(1):87. PubMed ID: 31856877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Solidarity(-ies) in Rare Diseases Research.
    Mascalzoni D; Petrini C; Taruscio D; Gainotti S
    Adv Exp Med Biol; 2017; 1031():589-604. PubMed ID: 29214593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.
    Baynam G; Bowman F; Lister K; Walker CE; Pachter N; Goldblatt J; Boycott KM; Gahl WA; Kosaki K; Adachi T; Ishii K; Mahede T; McKenzie F; Townshend S; Slee J; Kiraly-Borri C; Vasudevan A; Hawkins A; Broley S; Schofield L; Verhoef H; Groza T; Zankl A; Robinson PN; Haendel M; Brudno M; Mattick JS; Dinger ME; Roscioli T; Cowley MJ; Olry A; Hanauer M; Alkuraya FS; Taruscio D; Posada de la Paz M; Lochmüller H; Bushby K; Thompson R; Hedley V; Lasko P; Mina K; Beilby J; Tifft C; Davis M; Laing NG; Julkowska D; Le Cam Y; Terry SF; Kaufmann P; Eerola I; Norstedt I; Rath A; Suematsu M; Groft SC; Austin CP; Draghia-Akli R; Weeramanthri TS; Molster C; Dawkins HJS
    Adv Exp Med Biol; 2017; 1031():55-94. PubMed ID: 29214566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of patient organizations in the rare disease ecosystem in India: an interview based study.
    Choudhury MC; Saberwal G
    Orphanet J Rare Dis; 2019 May; 14(1):117. PubMed ID: 31142331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rarecare: A policy perspective on the burden of rare diseases on caregivers in Latin America.
    Dias AG; Daher A; Barrera Ortiz L; Carreño-Moreno S; Hafez H SR; Jansen AM; Rico-Restrepo M; Chaparro-Diaz L
    Front Public Health; 2023; 11():1127713. PubMed ID: 36935700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policies and actions to tackle rare diseases at European level.
    Montserrat A; Taruscio D
    Ann Ist Super Sanita; 2019; 55(3):296-304. PubMed ID: 31553326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of Kenya's cancer policies to improve access to cancer testing and treatment in the country.
    Makau-Barasa LK; Greene S; Othieno-Abinya NA; Wheeler SB; Skinner A; Bennett AV
    Health Res Policy Syst; 2020 Jan; 18(1):2. PubMed ID: 31910868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.
    Stein S; Bogard E; Boice N; Fernandez V; Field T; Gilstrap A; Kahn SR; Larkindale J; Mathieson T
    Orphanet J Rare Dis; 2018 Jan; 13(1):18. PubMed ID: 29357903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
    Choudhury MC; Saberwal G
    Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.